替莫唑胺和洛莫司汀哪个好？

Glioma is one of the most malignant common diseases in the nervous system. It has the characteristics of high recurrence rate and fatality rate. In clinical practice, surgical treatment combined with radiotherapy, chemotherapy, endocrine therapy and other comprehensive treatments are often used, which can correspondingly improve the short-term treatment effect of patients. Temozolomide and lomustine are both very good drugs for this disease. So, which one is better, temozolomide or lomustine?

Which is better, temozolomide or lomustine?

Research purpose: To compare the efficacy, survival time and adverse reactions of temozolomide (TMZ) and lomustine (CCNU) in the treatment of brain glioma.

Research methods: 64 patients with first-time postoperative glioma were randomly divided into TMZ group and CCNU group, 32 cases in each group. Patients in the two groups were first given conventional radiotherapy, 2Gy/d, 5d/W, lasting 4~6W in total, with a total radiation dose of 50~60 Gy. Chemotherapy was started 1 week after radiotherapy ended. The TMZ group was orally administered TMZ (0.015~0.02) mg/(cm2·d), 5 d/W, and every 5 days was a course of treatment. The interval between each course of treatment was 23 days, and 28 days was a treatment cycle. 3 to 5 cycles were administered according to the patient's tolerance. The CCNU group was orally administered CCNU (0.005 -0.006)mg/(cm2·d), 5d/W, and the treatment course and cycle were the same as those of the TMZ group.

Research results: The efficacy of the TMZ group was significantly better than that of the CCNU group (U=1.9675, P=0.0245). The average survival time of the TMZ group was (14.5±2.5) months, which was significantly higher than that of the CCNU group (10.5±1.5) months. The incidence of nausea, vomiting and fatigue in the TMZ group was significantly lower than that of the CCNU group, and the degree of bone marrow suppression in the TMz group was significantly lower than that of the CCNU group.

Conclusion

Temozolomide can significantly reduce tumor volume, prolong the patient's survival period, have fewer side effects, and improve the patient's quality of life than lomustine, and is worthy of clinical promotion and application. However, it is not up to the patient to decide which drug to use clinically. It is up to the doctor to judge the most suitable drug for you based on your relevant examination results.

Recommended related articles: